GlassScriptPhysician profile
Matthew P Brooks
NPI 1386835148
$3,693.38
in general payments reported to CMS, 2019-2025
17 companies · $881 in 2025
The $881 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $137 · 2021: $449 · 2022: $549 · 2023: $251 · 2024: $889 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,721 · Entertainment: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.93 |
| Entertainment | $299.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,166.23 | 2019-2025 | Simbrinza, Precision 1, Total30 |
| Coopervision INC. | $476.87 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $452.52 | 2022-2025 | Infuse, Biotrue One Day |
| Optos, INC. | $405.66 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $206.75 | 2019-2021 | |
| New World Medical,INC. | $178.48 | 2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Glaukos Corporation | $161.86 | 2025 | Istent Infinite, Idosetr |
| Allergan, INC. | $123.07 | 2022 | |
| Eyevance Pharmaceuticals LLC | $121.50 | 2019 | |
| Kala Pharmaceuticals, INC. | $118.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $95.63 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $57.50 | 2022 | |
| Dompe US, INC. | $48.04 | 2024-2025 | Oxervate |
| Lombart Brothers, INC. | $34.48 | 2025 | Opd-III |
| Shire North American Group INC | $18.15 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $14.31 | 2021 | |
| Abbvie INC. | $13.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.